Polymorphic forms of 1-′4-(5-cyanoindol-3-yl)butyl-4-(2-carbamoylbenzofuran-5-yl)piperazine hydrochloride

  • US 8,236,804 B2
  • Filed: 05/04/2011
  • Issued: 08/07/2012
  • Est. Priority Date: 06/19/2001
  • Status: Active Grant
First Claim
Patent Images

1. A method of treating a major depressive disorder, the method comprising:

  • administering to a patient in need thereof a pharmaceutical composition comprising an effective amount of a compound which is 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoyl-benzofuran-5-yl)-piperazine hydrochloride anhydrate in crystalline modification IV (Form IV) having at least five characteristic peaks selected from the degrees two-theta values corresponding to 9.08±

    0.1, 12.85±

    0.1, 14.50±

    0.1, 16.89±

    0.1, 18.89±

    0.1, 20.43±

    0.1, 21.72±

    0.1, 24.61±

    0.1, 27.35±

    0.1 and 28.18±

    0.1 and one or more conventional auxiliary substances and/or carriers, wherein the major depressive disorder is treated in the patient.

View all claims
    ×
    ×

    Thank you for your feedback

    ×
    ×